EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

A Cohort Study of 38 Classic Wiskott-Aldrich Syndrome Cases with Six Novel Mutations

Anahita Razaghian, Mohsen Badalzadeh, Amir Ali Hamidieh, Raheleh Shokouhi Shoormasti, Nasrin Behniafard, Massoud Houshmand, Leila Moradi, Samin Alavi, Maryam Behfar, Masoud Movahedi, Mohammad Gharagozlou, Tahereh Rostami und 13 weitere

Journal of Clinical Immunology · 2026

DOI: 10.1007/s10875-026-01986-3 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Clinical Immunology, 2026. Verfasst von Anahita Razaghian und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Clinical Immunology, Hakim Children's Hospital, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Wiskott-Aldrich Syndrome, Mutation, Wiskott-Aldrich Syndrome Protein. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Immunology, Asthma, and Allergy Research Institute, Tehran University of Medical Sciences..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Wiskott-Aldrich syndrome (WAS) is an X-linked immunodeficiency characterized by eczema, microthrombocytopenia, and recurrent infections. This study evaluates the frequency of clinical manifestations and overall outcomes in WAS patients, comparing those who received hematopoietic stem cell transplantation (HSCT) with those who did not. METHODS: Thirty-eight boys with a definite diagnosis of WAS were retrospectively evaluated in the Immunology, Asthma, and Allergy Research Institute registry in Tehran from 2006 to 2023. RESULTS: The median ages at symptom onset, diagnosis, and delay to diagnosis were 3.5, 7.5, and 4.5 months, respectively. The clinical presentations include allergies in 38 (100%), infection in 37 (97.4%), hemorrhage in 36 (94.7%), autoimmunity in 14 (36.8%), and malignancies or myelodysplasia syndrome in 3 (7.9%) patients. Although microthrombocytopenia is a hallmark of WAS, 34.4% of our cases had normal platelet size. The WAS gene analysis in 36 of 38 patients identified six novel mutations. Sixteen patients underwent HSCT. Disease-free survival was reported in 10 (62.5%) of them, whereas 6 (37.5%) of them were deceased. The mortality rate in non-transplant patients was 15/22 (68.2%). CONCLUSION: Most WAS patients experienced atopy, recurrent infections, and bleeding. Moreover, autoimmunity and malignancies have increased relative to the general population. Moreover, the mortality rate is high, especially among those who did not receive HSCT. Keeping in mind that thrombocytopenia alongside eczema and/or infection in a male infant can be the presentation of this fatal disease. Early diagnosis and treatment could be lifesaving and prevent severe morbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wiskott-Aldrich SyndromeMutationWiskott-Aldrich Syndrome ProteinHumansMaleInfantHematopoietic Stem Cell TransplantationChild, PreschoolRetrospective StudiesIranChild

Stichwörter der Autor:innen

Hematopoietic stem cell transplantationInborn errors of immunityThrombocytopeniaWiskott-Aldrich syndrome

Substanzen

Wiskott-Aldrich Syndrome ProteinWAS protein, human

Autor:innen und Institutionen

  • Department of Allergy and Clinical Immunology, Hakim Children's Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.
  • Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Children Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • National Institute for Genetic Engineering and Biotechnology, Tehran, Iran.

Förderung

  • Immunology, Asthma, and Allergy Research Institute, Tehran University of Medical Sciences.

Zitieren

APA

Razaghian, A., Badalzadeh, M., Hamidieh, A. A., Shokouhi Shoormasti, R., Behniafard, N., Houshmand, M., Moradi, L., Alavi, S., Behfar, M., Movahedi, M., Gharagozlou, M., Rostami, T., Moussavi, F., Fallahpour, M., Shariat, M., Parvaneh, N., Shafiei, A., Ahanchian, H., Babaei, D., …, & Pourpak, Z. (2026). A Cohort Study of 38 Classic Wiskott-Aldrich Syndrome Cases with Six Novel Mutations. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-026-01986-3

Vancouver

Razaghian A, Badalzadeh M, Hamidieh AA, Shokouhi Shoormasti R, Behniafard N, Houshmand M, et al. A Cohort Study of 38 Classic Wiskott-Aldrich Syndrome Cases with Six Novel Mutations. Journal of Clinical Immunology. 2026. doi:10.1007/s10875-026-01986-3

BibTeX
@article{Razaghian2026,
  author = {Razaghian, Anahita and Badalzadeh, Mohsen and Hamidieh, Amir Ali and Shokouhi Shoormasti, Raheleh and Behniafard, Nasrin and Houshmand, Massoud and Moradi, Leila and Alavi, Samin and Behfar, Maryam and Movahedi, Masoud and Gharagozlou, Mohammad and Rostami, Tahereh and Moussavi, Farideh and Fallahpour, Morteza and Shariat, Mansoureh and Parvaneh, Nima and Shafiei, Alireza and Ahanchian, Hamid and Babaei, Delara and Bemanian, Mohammad Hassan and Radmehr, Roshanak and Khademi, Reyhaneh and Shamlou, Somayeh and Fazlollahi, Mohammad Reza and Pourpak, Zahra},
  title = {A Cohort Study of 38 Classic Wiskott-Aldrich Syndrome Cases with Six Novel Mutations},
  journal = {Journal of Clinical Immunology},
  year = {2026},
  doi = {10.1007/s10875-026-01986-3}
}
Kostenlos starten →